Mirum Pharmaceuticals, Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Livmarli at $133.4 million, 72% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
671
|
186
|
176
|
160
|
149
|
133
|
128
|
112
|
99
|
| Livmarli |
482
+51.8%
share 71.9%
|
133
+44.7%
share 71.9%
|
129
+46.0%
share 73.0%
|
114
+55.4%
share 71.2%
|
106
+66.0%
share 71.4%
|
92
share 69.3%
|
88
share 69.0%
|
73
share 65.6%
|
64
share 64.5%
|
| Bile Acid Medicines |
188
+22.3%
share 28.1%
|
52
+28.2%
share 28.1%
|
48
+19.9%
share 27.0%
|
46
+20.1%
share 28.8%
|
43
+20.4%
share 28.6%
|
41
share 30.7%
|
40
share 31.0%
|
38
share 34.4%
|
35
share 35.5%
|
| License And Other Revenue |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
-0
share -0.0%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MIRM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1759425
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.